[Checkpoint inhibitors for cancer therapy]

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Checkpoint inhibitors represent a significant advancement in cancer therapy.
• These therapies activate the immune system against tumors by targeting specific cell surface proteins known as checkpoints.
• Approved inhibitors target CTLA-4 and PD-1/PD-L1 pathways.

Purpose of the Study:

• To provide an overview of the mechanism of action for approved checkpoint inhibitors.
• To summarize the current status of clinical development for these therapies.
• To discuss strategies for improving treatment efficacy.

Main Methods:

• Review of approved checkpoint inhibitors (monoclonal antibodies targeting CTLA-4, PD-1/PD-L1).
• Analysis of their application in various tumor types (e.g., lung, kidney, urothelial carcinoma, head and neck cancer, melanoma, Hodgkin lymphoma).
• Examination of current clinical development and future therapeutic strategies.

Main Results:

• Checkpoint inhibitors have enabled long-term survival in some patients with advanced cancers.
• Efficacy is limited to a subset of patients, varying by tumor type.
• Predictive biomarkers, such as PD-L1 expression, are crucial for patient selection.

Conclusions:

• Checkpoint inhibitors have revolutionized cancer treatment, offering durable responses in select patients.
• Improving patient selection through biomarkers and developing combination therapies are key to enhancing efficacy.
• Mandatory PD-L1 testing is implemented for specific indications to optimize patient benefit.